Too much of a good thing: A retrospective study of β-lactam concentration-toxicity relationships

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 10, 2017, Pages 2891-2897

  Imani, Sahand ^a,b   Buscher, Hergen ^b,c   Marriott, Debbie ^b,c   Gentili, Sheridan ^d   Sandaradura, Indy ^c,e  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUCLOXACILLIN; MEROPENEM; PIPERACILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; TOXIC CONCENTRATION; ADVERSE DRUG REACTION; AGED; BACTERIAL INFECTION; BLOOD; CLOSTRIDIUM INFECTION; INCIDENCE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; TOXICITY AND INTOXICATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLOXACILLIN; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PIPERACILLIN; RETROSPECTIVE STUDIES; THIENAMYCINS;

EID: 85029739585     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx209     Document Type: Article

References (38)

1. Roberts JA, Norris R, Paterson DL et al. Therapeutic drugmonitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36
2. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic reviewof the pharmacokinetics of b-lactams. Crit Care 2011; 15: R206
3. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 2011; 72: 381-93
4. Beumier M, Casu GS, Hites M et al. Elevated b-lactam concentrations are associated with neurological deterioration in ICU septic patients. Minerva Anestesiol 2015; 81: 497-506
5. Fugate JE, Kalimullah EA, Hocker SE et al. Cefepime neurotoxicity in the ICU: a cause of severe, underappreciated encephalopathy. Crit Care 2013; 17: R264
6. Slama TG. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care 2008; 12: 233
7. Lagacé-Wiens P, Rubinstein E. Adverse reactions to b-lactam antimicrobials. Expert Opin Drug Saf 2012; 11: 381-99
8. Vincent JL,Moreno R, Takala J et al. The SOFA (Sepsis-relatedOrgan Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74
10. Alberti C, Brun-Buisson C, Chevret S et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit CareMed 2005; 171: 461-8
11. Adam N, Kandelman S, Mantz J et al. Sepsis-induced brain dysfunction. Expert Rev Anti Infect Ther 2013; 11: 211-21
12. Teasdale G, Jennett B. Assessment and prognosis of coma after head injury. Acta Neurochir (Wien) 1976; 34: 45-55
13. MeredithW, Rutledge R, Fakhry SM et al. The conundrum of the Glasgow Coma Scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores. J Trauma AcuteCareSurg 1998; 44: 839-45
14. Bhattacharyya S, Darby RR, Raibagkar P et al. Antibiotic-associated encephalopathy. Neurology 2016; 86: 963-71
15. Roncon-Albuquerque R Jr, Pires I, Martins R et al. Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection. Neth JMed 2009; 67: 72-5
16. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42: 1843-50
17. Chow KM, Szeto CC, Hui AC et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003; 23: 369-73
18. Zhang J, Huang C, Li H et al. Antibiotic-induced neurotoxicity in dialysis patients: a retrospective study. Ren Fail 2013; 35: 901-5
19. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 1: R31
20. Aithal GP, Watkins PB, Andrade RJ et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15
21. Brown KA, Fisman DN, Moineddin R et al. The magnitude and duration of Clostridium difficile infection risk associatedwith antibiotic therapy: a hospital cohort study. PLoS One 2014; 9: e105454
22. McDonald C, CottaMO, Little PJ et al. Is high-dose b-lactamtherapy associated with excessive drug toxicity in critically ill patients? Minerva Anestesiol 2016; 82: 957-65
23. ChowKM,Hui AC, Szeto CC. Neurotoxicity induced by b-lactamantibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24: 649-53
24. De Sarro A, De Sarro GB, Ascioti C et al. Epileptogenic activity of some b-lactam derivatives: structure-activity relationship. Neuropharmacology 1989; 28: 359-65
25. Grøndahl TØ, Langmoen IA. Epileptogenic effect of antibiotic drugs. J Neurosurg 1993; 78: 938-43
26. Lin CS, Cheng CJ, Chou CH et al. Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. AmJMed Sci 2007; 333: 181-4
27. Tong MKH, Siu YP, Yung CY et al. Piperacillin/tazobactam-induced acute delirium in a peritoneal dialysis patient. Nephrol Dial Transplant 2004; 19: 1341
28. Huang WT, Hsu YJ, Chu PL et al. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009; 37: 374-6
29. Tamma PD, Turnbull AE, Harris AD et al. Less ismore: combination antibiotic therapy for the treatment of gram-negative bacteremia in pediatric patients. JAMA Pediatr 2013; 167: 903-10
30. Tune BM. Nephrotoxicity of b-lactam antibiotics: mechanisms and strategies for prevention. Pediatr Nephrol 1997; 11: 768-72
31. Pratt JA, Stricherz MK, Verghese PS et al. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. Pediatr Blood Cancer 2014; 61: 366-8
32. Jensen JS, Hein L, Lundgren B et al. Kidney failure related to broadspectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial.BMJ Open 2012; 2: e000635
33. Leitner JM, GraningerW, Thalhammer F. Hepatotoxicity of antibacterials: pathomechanisms and clinical data. Infection 2010; 38: 3-11
34. Andrews E, Daly AK. Flucloxacillin-induced liver injury. Toxicology 2008; 254: 158-63
35. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9
36. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridiumdifficile colonization resistance. Trends Microbiol 2012; 20: 313-9
37. Brown KA, Khanafer N, Daneman N et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57: 2326-32
38. Waikar SS, Betensky RA, Emerson SC et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012; 23: 13-21